2018 In the first three quarters of the year, the combined share of batch releases for the top ten vaccine products in China has already exceeded 88% In the following section, the Forward Industry Research Institute will analyze China’s vaccine industry’s batch-release data for the first three quarters from the perspective of product sub‑categories.

　　 I. Rabies Vaccine

　　From 2018 year 1-9 Looking at the monthly batch-release data for rabies vaccines in China, the overall trend shows fluctuations; however, 7 The month recorded exceptionally low figures; according to the analysis by the Forward Industry Research Institute, this was primarily due to… " Changchun Changsheng Vaccine " Impact of the incident.

　　Prior to this incident ( 2018 year 7 month) Changchun Changsheng ranks third among domestic rabies vaccine suppliers, even though… 7-9 The monthly batch release volume for three consecutive months was 0 In the first three quarters, it still ranked fourth nationwide, underscoring its prominent position in China’s rabies vaccine market. Precisely because it commands a substantial market share, this incident has triggered widespread public panic and outrage.

　　From the perspective of rabies vaccine sub‑products, they are currently mainly divided into four types: lyophilized human rabies vaccine ( True cells), lyophilized human rabies vaccine (human diploid cells), human rabies vaccine ( True cells), human rabies vaccine (hamster kidney cells), from 2018 Looking at the specific performance for the first three quarters of the year, the freeze-dried human rabies vaccine ( True Cell‑based vaccines are currently the mainstream products in the rabies vaccine market.

　　 II. Hepatitis B Vaccine

　　2018 year 1-9 Month, the total batch release volume of China’s hepatitis B vaccine 5329.08 Ten thousand (bottles, vials), viewed month by month, 1 Month, 3 Month, 4 The monthly batch release volume is relatively high, and... 900 Approximately ten thousand (bottles, vials); 7、8 The monthly batch release volumes are all at 600 Over ten thousand (bottles, vials), relatively speaking, 6 The monthly batch release volume was the lowest, at only 59.27 Ten thousand (bottles, vials).

　　From the perspective of hepatitis B vaccine manufacturers, in the first three quarters, the total number of companies producing hepatitis B vaccines in China was 5 Among them, Kangtai Biological and Hanxin Biological have relatively high batch-release volumes, accounting for respectively 44% and 34% ; additionally 3 The three companies are Jintan Bio, Walvax Biotechnology, and the foreign-invested enterprise GlaxoSmithKline, with respective shares of 15%、4% and 3%。

　　From a product perspective, hepatitis B vaccines are currently mainly categorized into three types: recombinant hepatitis B vaccine (Hansenula yeast), recombinant hepatitis B vaccine (Saccharomyces cerevisiae), and recombinant hepatitis B vaccine (…). CHO cells), in terms of the share of wholesale dispensing volume, the first two products currently hold a relatively large market share, 2018 The respective proportions for the first three quarters of the year are: 38% and 47% ; Recombinant hepatitis B vaccine ( CHO The proportion of batch release volume for cells is 15% , relatively few.

　　 Three-, Ten-, White-, and Diphtheria-Tetanus-Pertussis vaccines

　　2018 year 1-9 Month, the total batch release volume of China’s BCG, DPT, and polio vaccines 4997.09 Ten thousand (bottles, vials), when examined month by month, the highest number is 4 Month, for 1136.77 Ten thousand (bottles, vials), 5 It has declined month by month since the beginning of the month, 2018 year 9 The monthly batch release volume is 317.28 Ten thousand (bottles, vials).

　　Based on the performance of vaccine manufacturers in the first three quarters, there are three production companies, with Wuhan Institute of Biological Products accounting for a significant share of batch release approvals. 94% , holding an absolute market advantage.

　　From the perspective of batch release volumes for individual product categories, the adsorbed acellular pertussis–diphtheria–tetanus combined vaccine currently dominates the market. 2018 The proportion for the first three quarters of the year is 83%。

　　 IV. Meningitis Vaccine

　　2018 year 1-9 Month, total batch release volume of meningitis vaccines in China 4820.97 Ten thousand (bottles, vials), viewed month by month, 1 Month, 5 Month, 8 The monthly batch release volumes are all at 600 Over ten thousand (bottles, vials), 4 Moon and 9 The monthly batch release volume is relatively small, falling short of 400 Ten thousand (bottles, vials).

　　From the perspective of enterprise share, 2018 In the first three quarters of the year, corporate market concentration remained relatively high, with the top three firms accounting for a combined market share of 90%。

　　From a product segmentation perspective, A group C The meningococcal polysaccharide vaccine is currently the mainstream meningitis vaccine product. 2018 Proportion for the first three quarters of the year 66%； A Meningococcal polysaccharide vaccine and ACYW135 The proportions of the group meningococcal polysaccharide vaccines are as follows: 27% and 7%。

　　 V. Polio Vaccine

　　2018 year 1-9 In [month], the total batch release volume of polio vaccine in China was [amount]. 4079.95 Ten thousand (bottles, vials), broken down by month, the highest number of batch releases was in… 5 Month, reaching 776.34 Ten thousand (bottles, vials), the lowest is 7 Month, for 255.97 Ten thousand (vials, doses). Overall, the monthly batch release volume of polio vaccine has remained relatively stable.

　　From the perspective of enterprises, 2018 In the first three quarters of the year, the main Chinese manufacturers of polio vaccines were primarily… 3 Home, where the proportion of batch release volume for Beishengyan Biotechnology is 66% , the advantages are quite evident.

　　 VI. Japanese Encephalitis Vaccine

　　2018 year 1-9 Month, total batch release volume of China’s Japanese encephalitis vaccine 4002.12 Ten thousand (bottles, vials), when examined month by month, generally show a fluctuating trend, with the highest number being… 2018 year 3 Month, reach 627.93 Ten thousand (bottles, vials), 5 Month, 6 Month, 9 The batch release volume for the past three months has also exceeded 500 Ten thousand (bottles, vials).

　　From a corporate perspective, China currently has three manufacturers of Japanese encephalitis vaccine, with a high degree of market concentration; the batch-release volumes of Chengdu Institute of Biological Products and Wuhan Institute of Biological Products account for, respectively, 61% and 33%。

　　From a product‑segment perspective, the live attenuated Japanese encephalitis vaccine is currently the market’s mainstream product. 2018 In the first three quarters of the year, the share reached 93.86% ; The batch release proportions of the lyophilized inactivated Japanese encephalitis vaccine and the inactivated Japanese encephalitis vaccine are, respectively, 5.95% and 0.19% 。

　　 VII. Measles, Mumps, and Rubella Vaccine

　　2018 year 1-9 Month, the total batch release volume of China’s measles-mumps-rubella vaccine amounted to 2194.42 Ten thousand (bottles, vials), when examined month by month, the highest number is 3 Month, for 420.2 Ten thousand (bottles, vials), the lowest is 2 Month, only 8.41 Ten thousand (bottles, vials).

　　From the perspective of enterprises, 2018 In the first three quarters of the year, the major manufacturers of measles, mumps, and rubella vaccines were: 5 Among them, the proportion of batch release volumes for Beijing Institute of Biological Products and Shanghai Institute of Biological Products is respectively 38% and 39% , is currently a leading manufacturer in the measles–mumps–rubella vaccine market.

　　By product category, the current measles‑mumps‑rubella vaccine market primarily comprises the following sub‑products: 4 Class, with the most common being the measles–mumps–rubella combined live attenuated vaccine, accounting for 55% ; secondly, the measles-rubella combined vaccine, accounting for 24% , the proportions of the measles–mumps combined attenuated live vaccine and the mumps attenuated live vaccine were respectively 5% and 16%